eli lilly glp 1 market share set to leapfrog Novo Nordisk in weight-loss drug race Eli Lilly Vs. Novo Nordisk:

CJC-1295 Without DAC and DPP-4 Resistance Research Research that led to the identification of the tetrasubstituted GRF backbone confirmed that all maleimido derivatives of hGRF(1-29) sharing the same four amino acid substitutions showed enhanced in vitro stability against DPP-IV and retained bioactivity in GH secretion assays in cultured rat anterior pituitary cells establishing that the tetrasubstituted scaffold itself is responsible for DPP-4 resistance, independent of the DAC albumin-binding moiety

It should also be noted that the safety profile of orforglipron in ATTAIN-1 was explicitly described as consistent with that of established injectable GLP-1 agents

Metabolic: Euglycemic DKA The risk of euglycemic DKA is very uncommon, but its a clinically important and real complication to be aware of in patients using GLP-1 agonists

10.3390/biom15010151 8 BarrettJ

You're better off eating at home

A Clinical trial of glutathione supplementation in autism spectrum disorders.